[go: up one dir, main page]

WO2008147763A8 - Mmp inhibitors and methods of use thereof - Google Patents

Mmp inhibitors and methods of use thereof Download PDF

Info

Publication number
WO2008147763A8
WO2008147763A8 PCT/US2008/064209 US2008064209W WO2008147763A8 WO 2008147763 A8 WO2008147763 A8 WO 2008147763A8 US 2008064209 W US2008064209 W US 2008064209W WO 2008147763 A8 WO2008147763 A8 WO 2008147763A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mmp inhibitors
mmp
inhibitors
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/064209
Other languages
French (fr)
Other versions
WO2008147763A1 (en
Inventor
Andrew M. Fryer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of WO2008147763A1 publication Critical patent/WO2008147763A1/en
Publication of WO2008147763A8 publication Critical patent/WO2008147763A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are MMP inhibitors having the Formula (I): wherein R1, R2 and Y are as defined herein, which are useful in the treatment and/or prevention of MMP-mediated diseases and disorders.
PCT/US2008/064209 2007-05-23 2008-05-20 Mmp inhibitors and methods of use thereof Ceased WO2008147763A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93975807P 2007-05-23 2007-05-23
US60/939,758 2007-05-23

Publications (2)

Publication Number Publication Date
WO2008147763A1 WO2008147763A1 (en) 2008-12-04
WO2008147763A8 true WO2008147763A8 (en) 2009-10-01

Family

ID=39884415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064209 Ceased WO2008147763A1 (en) 2007-05-23 2008-05-20 Mmp inhibitors and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2008147763A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60033809T2 (en) * 1999-06-04 2007-12-06 Astrazeneca Ab INHIBITORS OF METAL PROTEINASES
WO2004032846A2 (en) * 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
RU2006123559A (en) * 2003-12-04 2008-01-10 Уайт (Us) BIARILSULPHONAMIDES AS MMP INHIBITORS
CN1894206A (en) * 2003-12-15 2007-01-10 日本烟草产业株式会社 N-substituted N-sulfonylaminocyclopropane compound and its pharmaceutical application
EP1694410B1 (en) * 2003-12-15 2010-04-14 Japan Tobacco, Inc. Cyclopropane derivatives and pharmaceutical use thereof
WO2008024784A1 (en) * 2006-08-22 2008-02-28 Array Biopharma, Inc. Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
WO2008147763A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2009011850A3 (en) Novel therapeutic compounds
WO2008033562A3 (en) Kinase inhibitor compounds
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2008049123A3 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2009085270A3 (en) Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2010077310A3 (en) Amide derivatives of ethacrynic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755941

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08755941

Country of ref document: EP

Kind code of ref document: A1